Cellectricon

Cellectricon is a leading provider of advanced cell-based screening services to accelerate drug discovery. Utilizing the company's Cellaxess® Elektra platform, its Discovery service offerings are well-suited for compound analysis in excitable primary cells and native tissues. The company’s services assist researchers in identifying phenotypic effects in highly relevant biological models early in the project lifecycle, adding significant value to decisions on whether to pursue or eliminate compounds, thereby saving substantial costs in the drug development process.